The honest headline on Botox® vs. Jeuveau®: they are more similar than different. Both are botulinum toxin type A. Both work by the same mechanism, on the same muscles, with roughly the same dosing, the same onset, and comparable duration. If you are treating frown lines, the difference a patient can feel between them is small.
The real differences are not clinical at all. They are regulatory — Jeuveau holds one FDA approval while Botox holds more than a dozen — and commercial, in manufacturer, price, and branding. This guide covers what actually separates them, what does not, and how to think about the choice as a patient or as an injector. For the broader class including Xeomin and Dysport, see our Botox vs. Xeomin vs. Dysport comparison.
Who Makes Jeuveau? Manufacturer and Origin
This is the most-asked question about Jeuveau, so it goes first.
Jeuveau is marketed in the United States by Evolus, a performance-beauty company headquartered in Newport Beach, California. Evolus is the brand owner and the commercial face of the product, but it does not manufacture it.
Jeuveau is manufactured in South Korea by Daewoong Pharmaceutical, which developed the toxin and licenses it to Evolus for U.S. aesthetic distribution. Outside the U.S., the same product is sold under other names in other markets.
For comparison, Botox is manufactured by Allergan, part of AbbVie since 2020, at a facility in Westport, Ireland.
Country of origin gets raised in consultations more than it should. Both products are FDA-approved, which means both were reviewed against the same U.S. standards regardless of where the plant sits. “Made in South Korea” is not a safety signal. It is worth knowing because patients ask — not because it should change a decision.
Botox vs. Jeuveau: What’s Actually the Same
Start here, because this is the larger list and most comparisons bury it.
- Same toxin type. Both are botulinum toxin type A, produced by Clostridium botulinum.
- Same mechanism. Both block acetylcholine release at the neuromuscular junction by cleaving SNAP-25. The muscle cannot receive the contraction signal, so it relaxes and the skin above it smooths.
- Same target. Both treat dynamic wrinkles — lines caused by repeated muscle movement. Neither does much for static lines etched in by sun damage and volume loss.
- Comparable molecular structure. Both are 900 kDa complexes that retain the accessory complexing proteins around the core toxin, unlike Xeomin.
- Roughly 1:1 dosing. Jeuveau units are generally treated as equivalent to Botox units — the two are the easiest pair in the class to swap. This is genuinely unusual; Dysport and Daxxify units are not interchangeable with Botox at all.
- Similar onset and duration. Both typically show softening in about three to five days, with full effect around two weeks, and results lasting roughly three to four months.
- Comparable safety profile. Both went through randomized controlled trials, and Jeuveau’s pivotal program included head-to-head comparison against Botox. Both carry the same class boxed warning about distant spread of toxin effect.
- Same side effects. Injection-site bruising and swelling, headache, and, less commonly, technique-dependent problems like eyelid or brow ptosis and asymmetry.
Be skeptical of any source claiming a dramatic experiential difference here. The differences below are real, but they are not felt in the mirror.
The Real Differences
FDA Indications — the Big One
This is the difference that matters most, and it is not close.
Jeuveau has exactly one FDA approval: temporary improvement of moderate to severe glabellar lines — frown lines — in adults. That is the entire label. It has no therapeutic indications at all.
Botox is approved for a long list spanning cosmetic and therapeutic use: glabellar lines, crow’s feet, forehead lines, chronic migraine, cervical dystonia, hyperhidrosis, overactive bladder, blepharospasm, strabismus, limb spasticity, and sialorrhea. Our guide to what Botox is covers the full range.
This is deliberate strategy, not deficiency. Evolus built Jeuveau as a cosmetic-only product. Skipping therapeutic development is faster and far cheaper, and that cost structure is what funds the lower price.
It also means that if you are a patient seeking treatment for migraine, sweating, or jaw clenching, Jeuveau is not the product being discussed — and if a provider offers it for those, they are using it off-label, which should be disclosed and consented as such.
Active Ingredient Name
Botox is onabotulinumtoxinA. Jeuveau is prabotulinumtoxinA. The different prefixes are an FDA requirement designed to stop clinicians from treating neuromodulators as generics of one another. They signal that these are distinct preparations from distinct manufacturing processes — not that they behave differently in tissue.
Price
Jeuveau generally comes to market at a lower price point than Botox. That is a consistent pattern rather than a fixed number: providers set their own prices, and promotions, packages, and loyalty programs make any stated figure unreliable. We are not going to quote a price, because anyone who does is guessing.
The mechanism behind the lower price is straightforward — a cosmetic-only development pathway costs a fraction of a dual cosmetic-and-therapeutic one, and Evolus prices to win share against an entrenched incumbent.
One caution for patients: because Jeuveau and Botox dose roughly 1:1, per-unit price comparison between these two is actually meaningful — which is not true for most brand comparisons in this category. Do not carry that habit over to Dysport.
Loyalty Programs
Rarely discussed clinically, frequently decisive commercially. Allergan’s consumer rewards ecosystem spans its whole portfolio and is one of the strongest retention tools in aesthetic medicine. Evolus runs its own program. For patients who treat regularly across multiple products, points accumulation is a real factor in where they spend.
Branding
Jeuveau is marketed as “Newtox” — explicitly positioned as the younger, aesthetics-first alternative, aimed at first-timers and at the prejuvenation and “baby Botox” conversation. Botox’s brand advantage is that its name became the word for the category.
Worth clearing up: “baby Botox” is a technique, not a product. It means smaller doses across more points for a softer, less frozen result, and it can be done with either product. Neither is inherently more “natural” than the other — that is the injector’s dosing, not the vial.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
Does Jeuveau Last as Long as Botox?
Broadly, yes. Both typically deliver roughly three to four months of cosmetic effect, and Jeuveau’s trials included direct comparison against Botox.
Some patients report a slightly faster onset with Jeuveau, and some injectors say the same. Treat that as an impression rather than an established finding — it is not a reliable basis for choosing.
What genuinely drives duration is not the brand:
- Dose. Under-dosing a strong muscle is the most common reason results fade early, and it gets blamed on the product constantly.
- Muscle mass. Stronger muscles metabolize through the effect faster.
- Metabolism and activity level. Highly active patients often report shorter duration.
- Treatment history. Patients treated consistently over years often find intervals lengthen as muscles weaken.
Our guide to how long Botox takes to work and how long it lasts covers the full timeline, and it applies substantially to Jeuveau.
Can You Use Botox and Jeuveau Together?
Not in the same muscle at the same appointment — there is no reason to, and it makes any adverse outcome impossible to attribute.
Using them in different regions during one visit is done, and it is not unsafe when a clinician manages total dosing and placement. A provider might use one product in the glabella and another for crow’s feet based on preference or product availability.
But be honest about why. There is rarely a clinical reason to mix, and the real drivers are usually inventory or pricing. If a patient is getting two products in one visit, they deserve to be told why in plain terms.
Which Should a Practice Carry?
For injectors, the calculus is mostly economic:
- Patient mix. A cosmetic-only practice loses nothing by carrying Jeuveau. A practice treating migraine or hyperhidrosis needs Botox regardless.
- Price sensitivity of your market. Jeuveau is a genuine tool for competing on price without cutting your own margin.
- Brand demand. Patients ask for Botox by name. Converting them costs chair time, every time.
- Supply diversification. Single-supplier dependence is a business risk. Practices that lived through allocation shortages learned it.
- Rebates. Loyalty structures on both sides are engineered to make switching costly. Model it before you assume the cheaper vial is cheaper.
Carrying both is common and defensible. It is also the answer that requires you to actually know your dosing, your injection sites, and your reconstitution protocol for each product rather than treating them as one inventory line.
Frequently Asked Questions
What is the difference between Botox and Jeuveau?
Both are botulinum toxin type A with the same mechanism, roughly 1:1 dosing, and comparable onset and duration. The real differences: Jeuveau holds one FDA approval (glabellar lines) with no therapeutic indications, while Botox holds more than a dozen; Jeuveau is made by Daewoong for Evolus and typically priced lower, while Botox is made by Allergan/AbbVie.
Who is the Jeuveau manufacturer?
Jeuveau is manufactured by Daewoong Pharmaceutical in South Korea and marketed in the United States by Evolus, based in Newport Beach, California. Evolus owns the U.S. aesthetic brand; Daewoong makes the product.
Where is Jeuveau made?
South Korea. Botox, by contrast, is manufactured in Westport, Ireland. Both are FDA-approved and were reviewed against the same U.S. standards.
Does Jeuveau last as long as Botox?
Yes, broadly — roughly three to four months for both, with comparable onset. Duration is driven far more by dose, muscle mass, metabolism, and treatment history than by which of these two products was used.
Does Jeuveau last longer than Botox?
No. There is no established evidence that Jeuveau outlasts Botox. Some patients and injectors report slightly faster onset, but that is anecdotal and should not drive the decision.
Is Jeuveau a good Botox alternative?
For frown lines and other cosmetic dynamic wrinkles, yes — it is FDA-approved, extensively trialed, and doses roughly 1:1 with Botox. For therapeutic indications like migraine or hyperhidrosis, it is not an alternative at all, because it has no therapeutic approvals.
Is Jeuveau the same as “Newtox”?
Yes. “Newtox” is Evolus’s marketing nickname for Jeuveau, not a separate product or a clinical term.
Can you get baby Botox with Jeuveau?
Yes. “Baby Botox” describes a technique — smaller doses spread over more injection points for a softer result — not a specific product. It can be done with either.
Is Jeuveau safe?
It has an FDA approval and a safety profile comparable to Botox, including the same class boxed warning regarding distant spread of toxin effect. As with any neuromodulator, most poor outcomes trace to injection technique rather than to the product. Follow standard aftercare — see our do’s and don’ts after Botox, which applies to both.
Learn to Inject Neuromodulators — Not Just One Brand
Botox and Jeuveau share a mechanism, a dosing ratio, and a risk profile. What they do not share is a label, and neither produces a good result on its own. Facial anatomy, dosing by muscle mass, injection depth, diffusion control, patient selection, off-label consent, and complication management are what decide the outcome.
Empire Medical Training has trained healthcare professionals in aesthetic medicine since 1998. Our Botox Training & Certification course is CME-accredited and hands-on, with live-patient injection under expert supervision, covering the neuromodulator class rather than a single product.
